# Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

> **NCT05152641** · PHASE2 · WITHDRAWN · sponsor: **BioAge Labs, Inc.**

## Conditions studied

- Acute Posthemorrhagic Anemia

## Interventions

- **DRUG:** BGE-117, 4mg
- **DIETARY_SUPPLEMENT:** Ferrous Sulfate
- **OTHER:** Matching Placebo
- **DRUG:** BGE-117, 12mg

## Key facts

- **NCT ID:** NCT05152641
- **Lead sponsor:** BioAge Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04
- **Primary completion:** 2023-04
- **Final completion:** 2024-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The program priority for execution of this clinical trial changed prior to enrollment of the first patient. The study was not withdrawn due to any safety concerns.
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152641, "Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05152641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*